ZA921230B - Improved activation of recombinant proteins - Google Patents

Improved activation of recombinant proteins

Info

Publication number
ZA921230B
ZA921230B ZA921230A ZA921230A ZA921230B ZA 921230 B ZA921230 B ZA 921230B ZA 921230 A ZA921230 A ZA 921230A ZA 921230 A ZA921230 A ZA 921230A ZA 921230 B ZA921230 B ZA 921230B
Authority
ZA
South Africa
Prior art keywords
recombinant proteins
amino acids
improved activation
helper sequences
relative hydrophobicities
Prior art date
Application number
ZA921230A
Other languages
English (en)
Inventor
Dorothea Ambrosius
Ambrosius Dorothea
Carola Dony
Dony Carola
Rainer Rudolph
Rudolph Rainer
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6425597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA921230(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of ZA921230B publication Critical patent/ZA921230B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dental Preparations (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Adhesive Tapes (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA921230A 1991-02-21 1992-02-20 Improved activation of recombinant proteins ZA921230B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4105480A DE4105480A1 (de) 1991-02-21 1991-02-21 Verbesserte aktivierung von rekombinanten proteinen

Publications (1)

Publication Number Publication Date
ZA921230B true ZA921230B (en) 1992-11-25

Family

ID=6425597

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA921230A ZA921230B (en) 1991-02-21 1992-02-20 Improved activation of recombinant proteins

Country Status (20)

Country Link
US (1) US5578710A (sv)
EP (1) EP0500108B1 (sv)
JP (1) JP2528232B2 (sv)
KR (1) KR950014493B1 (sv)
AT (1) ATE144284T1 (sv)
AU (1) AU641081B2 (sv)
CA (1) CA2061569C (sv)
CZ (1) CZ282744B6 (sv)
DE (2) DE4105480A1 (sv)
DK (1) DK0500108T3 (sv)
ES (1) ES2093122T3 (sv)
FI (1) FI106029B (sv)
GR (1) GR3021395T3 (sv)
HU (1) HU214881B (sv)
IE (1) IE920276A1 (sv)
IL (1) IL101024A (sv)
MX (1) MX9200709A (sv)
NO (1) NO300329B1 (sv)
NZ (1) NZ241570A (sv)
ZA (1) ZA921230B (sv)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022431A1 (en) * 1993-03-30 1994-10-13 Pharmacia Ab Controlled release preparation containing a salt of morphine

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
MXPA03002046A (es) 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
CA2452582C (en) 2001-07-11 2013-01-22 Maxygen Holdings, Ltd. G-csf conjugates
US7557195B2 (en) 2002-03-20 2009-07-07 Biopolymed, Inc. Stoichiometric conjugates of biocompatible polymers at the unpaired cysteine residue of the wild-type G-CSF
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
WO2009023566A2 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
AU2011223627B2 (en) 2010-03-04 2015-06-18 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
CA2789615A1 (en) * 2010-03-17 2011-09-22 Biogenerix Gmbh Method for obtaining biologically active recombinant human g-csf
CA2794740C (en) 2010-04-01 2019-12-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
CA2876099A1 (en) * 2012-08-02 2014-02-06 F. Hoffmann-La Roche Ag Method for producing monomeric and multimeric molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532207A (en) * 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
DK55685A (da) * 1985-02-07 1986-08-08 Nordisk Gentofte Enzym eller enzymkompleks med proteolytisk aktivitet
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US5082775A (en) * 1984-05-11 1992-01-21 Berlex Laboratories, Inc. Efficient process for isolating insoluble heterologous protein using non-ionic detergents
US4948729A (en) * 1985-03-25 1990-08-14 Cetus Corporation Production of soluble recombinant proteins
US4783415A (en) * 1985-03-28 1988-11-08 Meiji Seika Kabushiki Kaisha Gene coding for signal peptides and utilization thereof
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3636903A1 (de) * 1985-12-21 1987-07-02 Hoechst Ag Fusionsproteine mit eukaryotischem ballastanteil
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
US5013653A (en) * 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500876A (ja) * 1987-03-20 1990-03-29 クリエイティブ・バイオマリキュールズ・インコーポレーテッド 組換えポリペプチドの製品およびその製造、単離および精製方法
AU1987088A (en) * 1987-06-24 1989-01-19 Novo Nordisk A/S A process for preparing a protein or polypeptide, a dna sequence coding for the polypeptide, a microorganism containing the dna sequence as well as the polypeptide and its use as a pharmaceutical preparation
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
ZA901719B (en) * 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5191063A (en) * 1989-05-02 1993-03-02 University Of Medicine And Dentistry Of New Jersey Production of biologically active polypeptides by treatment with an exogenous peptide sequence
US5115102A (en) * 1989-07-21 1992-05-19 Monsanto Company Variant proteins and polypeptides possessing enhanced affinity for immobilized-metal affinity matrices
ATE154073T1 (de) * 1990-08-20 1997-06-15 Novo Nordisk As Prozess für die herstellung von biologisch aktivem igf-1 durch verwendung von amino-terminal verlängertem igf-1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022431A1 (en) * 1993-03-30 1994-10-13 Pharmacia Ab Controlled release preparation containing a salt of morphine

Also Published As

Publication number Publication date
JP2528232B2 (ja) 1996-08-28
DE4105480A1 (de) 1992-08-27
CA2061569C (en) 2000-10-24
KR920016464A (ko) 1992-09-24
NO300329B1 (no) 1997-05-12
NZ241570A (en) 1994-09-27
AU1094892A (en) 1992-08-27
ATE144284T1 (de) 1996-11-15
DE59207351D1 (de) 1996-11-21
NO920671L (no) 1992-08-24
US5578710A (en) 1996-11-26
CS49992A3 (en) 1992-09-16
GR3021395T3 (en) 1997-01-31
HU214881B (hu) 1998-07-28
MX9200709A (es) 1992-09-01
EP0500108A3 (en) 1993-04-07
FI920742A (fi) 1992-08-22
JPH05244977A (ja) 1993-09-24
ES2093122T3 (es) 1996-12-16
DK0500108T3 (da) 1997-03-24
IE920276A1 (en) 1992-08-26
IL101024A0 (en) 1992-11-15
CZ282744B6 (cs) 1997-09-17
HU9200548D0 (en) 1992-04-28
IL101024A (en) 1996-06-18
AU641081B2 (en) 1993-09-09
FI106029B (sv) 2000-11-15
NO920671D0 (no) 1992-02-20
CA2061569A1 (en) 1992-08-22
HUT68021A (en) 1995-04-04
FI920742A0 (fi) 1992-02-20
EP0500108A2 (de) 1992-08-26
EP0500108B1 (de) 1996-10-16
KR950014493B1 (ko) 1995-12-02

Similar Documents

Publication Publication Date Title
ZA921230B (en) Improved activation of recombinant proteins
DE69033040D1 (de) Verfahren zur Herstellung von biologisch aktivem Protein (z.B. TGF)
DE69529219D1 (en) Helicobacter proteine und impstoffe
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
AU669483B2 (en) Nucleotide sequences and resistance proteins cycloheximide
ES2124247T3 (es) Conjugado de calcitonina y de polietilenglicol.
DE68907635D1 (de) Loetmaterial fuer brillengestelle und brillengestelle, bei denen dieses loetmaterial verwendet ist.
DK0652903T3 (da) Nyt humant rekombinant gammainterferon
AU3902489A (en) Non-glycosylated, recombinant human IL2 in the reduced form, the process for obtaining it and its use as a medicament
SE9602822D0 (sv) New receptor
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
ES2078229T3 (es) Procedimiento para la preparacion de un polipeptido similar a la motilina y su expresion.
IT8719551A0 (it) Plasmidi ricombinanti utili perl'espressione in bacillus di proteine eterologhe.
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
DE69534738D1 (de) Leukocyten-aktivierender Faktor
GB9604518D0 (en) Novel compounds
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.